[Predictive factors for bone metastases of prostate cancer]
- PMID: 26922017
[Predictive factors for bone metastases of prostate cancer]
Abstract
Objective: To investigate the correlation between a diverse of clinical factors and bone metastases of prostate cancer.
Methods: The clinical data of 80 patients with prostate cancer were collected and analyzed. The correlations of age, alkaline phosphotase (ALP), prostate specific antigen (PSA), erythrocyte sedimentation rate (ESR), Gleason score, and expressions of androgen receptor (AR) and Ki-67 with bone metastases were analyzed by one-way ANOVA and Logistic regression analysis. The cutoff value, sensitivity and specificity of the independent correlation factors were calculated.
Results: Forty-five of the 80 patients (56%) were found to have bone metastasis, who had significantly older age and higher levels of ALP, PSA, ESR, Gleason score, and expressions of AR and Ki-67 than those without bone metastasis (P<0.05). Logistic regression analysis identified PSA, Gleason score and AR expression as independent factors correlated with bone metastasis with OR (95% CI) of 1.005 (1.001, 1.009) (P=0.008), 5.356 (1.431, 20.039) (P=0.013), and 18.594 (2.460, 140.524) (P=0.005), respectively. The cutoff values of PSA, Gleason Score and AR were 67.1 ng/ml, 7.5, and 2.5, respectively; their sensitivities were 55.6%, 75.6%, and 84.0% for predicting bone metastasis with specificities of 97.1%, 82.9%, and 91.4%, respectively.
Conclusion: Of the factors analyzed, PSA, Gleason score and AR expression, but not age, ALP, PSA, ESR, or Ki-67 expression, are the predictive factors of bone metastasis of prostate cancer.
Similar articles
-
Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma.Med Sci Monit. 2017 Apr 12;23:1768-1774. doi: 10.12659/msm.900977. Med Sci Monit. 2017. PMID: 28400549 Free PMC article.
-
Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.Rev Esp Med Nucl Imagen Mol. 2013 Sep-Oct;32(5):286-9. doi: 10.1016/j.remn.2013.01.002. Epub 2013 Mar 9. Rev Esp Med Nucl Imagen Mol. 2013. PMID: 23478119 Clinical Trial.
-
Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.Int J Urol. 2008 May;15(5):419-22. doi: 10.1111/j.1442-2042.2008.02029.x. Int J Urol. 2008. PMID: 18452459
-
Predicting the risk of bone metastasis in prostate cancer.Cancer Treat Rev. 2014 Feb;40(1):3-11. doi: 10.1016/j.ctrv.2013.07.001. Epub 2013 Jul 26. Cancer Treat Rev. 2014. PMID: 23896177 Review.
-
Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer.Front Endocrinol (Lausanne). 2024 Feb 7;15:1338420. doi: 10.3389/fendo.2024.1338420. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38384968 Free PMC article. Review.
Cited by
-
Predicting castration-resistant prostate cancer after combined androgen blockade.Oncotarget. 2017 Nov 1;8(62):105458-105462. doi: 10.18632/oncotarget.22246. eCollection 2017 Dec 1. Oncotarget. 2017. PMID: 29285263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous